09.14.23
Probiotix Health Plc has launched a new formulation designed for high end heart health supplements and online brands in the nutraceuticals market looking to expand cardiovascular health offerings.
Cholbiome VH is designed to support heart and vascular health through multiple mechanisms of action. The formulation contains Lactobacillus plantarum LPLDL from Probiotix, K2Vital Delta, a vitamin K2 as menaquinone-7 ingredient from Norwegian-based kappa Bioscience AS, and Thiamine, a form of vitamin B1 which has a recognized European Food Safety Authority (EFSA)-recognized health claim that it ‘contributes to the normal function of the heart.’
CholBiome VH is a finished supplement dosage format, which is available as a private label product.
“The British Heart Foundation reports that each year around 60 million people around the world develop a heart or circulatory disease,” said Steen Andersen, CEO at Probiotix. “To this day, cardiovascular disease (CVD) remains one of the world’s biggest killers, with around 5 million men and 4.2 million women dying from coronary heart disease in 2019. With up to 85% of CVD deaths preventable, ProBiotix is working with key opinion leaders, academics and industry professionals to help improve heart health worldwide through the CholBiome range.”
“As a result of our work in the industry, we are pleased to launch CholBiomeVH. This vegan, dairy-and-gluten-free food supplement contains three ingredients within a capsule with gastric acid protection technology. The first ingredient is our patented probiotic LPLDL, which has clinically demonstrated efficacy to reduce total cholesterol by up to 34.6%, LDL cholesterol by 28.4% and apolipoprotein (ApoB) by 28.6%. High LDL cholesterol and ApoB are recognized key risk biomarkers that contribute to vascular plaque formation and the development of atherosclerosis. The second is Thiamine to contribute to the normal function of the heart, and finally K2VITAL DELTA to contribute to normal blood coagulation and ensure superior bioavailability, quality and purity to support the reduction of vascular calcification and plaque formation.”
Vitamin K2 was included because of its established dual-action regulation of calcium in the human body to maintain calcium balance by activating the enzyme Matrix Gla Protein (MGP), which diverts calcium from arteries.
When combined, LPLDL and K2Vital Delta are formulated to synergistically work to support healthy cholesterol, apolipoprotein B, and calcium deposits in the arteries.
“Probiotix is proud to be developing finished formulations that can support cardiovascular health,” Andersen said. “Today, as many as 2.6 million people in the UK have narrowing of arteries around the heart, while in the U.S. more than 40% of middle-aged with no known heart disease had signs of atherosclerosis. CholBiome is designed to reduce multiple key risk biomakrers that contribute to plaque formation, so that consumers can live healthier for longer.”
Cholbiome VH is designed to support heart and vascular health through multiple mechanisms of action. The formulation contains Lactobacillus plantarum LPLDL from Probiotix, K2Vital Delta, a vitamin K2 as menaquinone-7 ingredient from Norwegian-based kappa Bioscience AS, and Thiamine, a form of vitamin B1 which has a recognized European Food Safety Authority (EFSA)-recognized health claim that it ‘contributes to the normal function of the heart.’
CholBiome VH is a finished supplement dosage format, which is available as a private label product.
“The British Heart Foundation reports that each year around 60 million people around the world develop a heart or circulatory disease,” said Steen Andersen, CEO at Probiotix. “To this day, cardiovascular disease (CVD) remains one of the world’s biggest killers, with around 5 million men and 4.2 million women dying from coronary heart disease in 2019. With up to 85% of CVD deaths preventable, ProBiotix is working with key opinion leaders, academics and industry professionals to help improve heart health worldwide through the CholBiome range.”
“As a result of our work in the industry, we are pleased to launch CholBiomeVH. This vegan, dairy-and-gluten-free food supplement contains three ingredients within a capsule with gastric acid protection technology. The first ingredient is our patented probiotic LPLDL, which has clinically demonstrated efficacy to reduce total cholesterol by up to 34.6%, LDL cholesterol by 28.4% and apolipoprotein (ApoB) by 28.6%. High LDL cholesterol and ApoB are recognized key risk biomarkers that contribute to vascular plaque formation and the development of atherosclerosis. The second is Thiamine to contribute to the normal function of the heart, and finally K2VITAL DELTA to contribute to normal blood coagulation and ensure superior bioavailability, quality and purity to support the reduction of vascular calcification and plaque formation.”
Vitamin K2 was included because of its established dual-action regulation of calcium in the human body to maintain calcium balance by activating the enzyme Matrix Gla Protein (MGP), which diverts calcium from arteries.
When combined, LPLDL and K2Vital Delta are formulated to synergistically work to support healthy cholesterol, apolipoprotein B, and calcium deposits in the arteries.
“Probiotix is proud to be developing finished formulations that can support cardiovascular health,” Andersen said. “Today, as many as 2.6 million people in the UK have narrowing of arteries around the heart, while in the U.S. more than 40% of middle-aged with no known heart disease had signs of atherosclerosis. CholBiome is designed to reduce multiple key risk biomakrers that contribute to plaque formation, so that consumers can live healthier for longer.”
